MannKind Corp., a biotechnology company headquartered in Westlake Village, reported $1.98 million in product sales, resulting in $32.9 million in net losses for the quarter ended Sept. 30. The company, which manufactures an inhalable insulin product called Afrezza, reported a cash burn of $23.3 million, ending the quarter with slightly more than $20 million in…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
